Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jennifer M. Bailey

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4750-106X; OpenAlex author ID A5000636834. Sources: funder_awards.

Their work

Papers
26 (first author 2, last author 14)
Trials
0
Grants
1
Labs led
2
Collaborators
59
Papers, trials and grants by year

2011: 1 grant · 2012: none · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers · 2024: 6 papers · 2025: none · 2026: 6 papers

Papers 26

  1. Mechanistic Insights Driving Translational Progress in Pancreatic Cancer. Last author DOI 10.1016/j.jcmgh.2025.101685↗
  2. Dietary Fat Content Influences PanIN Progression and Pancreatic Cancer Development in Mice. Last author DOI 10.1158/2767-9764.crc-25-0777↗
  3. ADA2-Functionalized OMVs Remodel the Tumor Microenvironment in Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics18080920↗
  4. Combination Immunotherapy Enhances Serial Radiofrequency Ablation Induced Systemic Antitumor Immunity in Pancreatic Cancer Last author DOI 10.64898/2026.04.05.713683↗
  5. Pulsed Field Ablation Enables Stromal Manipulation and Tumor Reduction in Pancreatic Ductal Adenocarcinoma Last author DOI 10.64898/2026.10.06.756887↗
  6. Oncogenic KRAS-MAPK signaling sustains a CD73 dependent therapeutic vulnerability in pancreatic cancer Last author DOI 10.64898/2026.10.20.760559↗
  7. EUS-guided radiofrequency ablation for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gie.2024.04.2926↗
  8. Increased Gremlin1 Expression in Pancreatic Ductal Adenocarcinoma Promotes a Fibrogenic Stromal Microenvironment. Co-author DOI 10.1097/mpa.0000000000002378↗
  9. The TGF-β superfamily as potential therapeutic targets in pancreatic cancer. First author DOI 10.3389/fonc.2024.1362247↗
  10. Editorial: Emerging anti-cancer compounds and immunomodulators for pancreatic cancer treatment. Last author DOI 10.3389/fonc.2024.1411836↗
  11. Lifestyle Medicine for the Prevention and Treatment of Pancreatitis and Pancreatic Cancer. Co-author DOI 10.3390/diagnostics14060614↗
  12. Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodu… Co-author DOI 10.37349/etat.2024.00263↗
  13. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-22-2553↗
  14. Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-22-0379↗
  15. The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer. Last author DOI 10.3389/fimmu.2023.1163585↗
  16. Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ducta… Last author DOI 10.3389/fonc.2022.995027↗
  17. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Last author DOI 10.1038/s41374-020-00490-5↗
  18. Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer Last author DOI 10.1038/s41374-021-00615-4↗
  19. Pancreatic cancer ductal cell of origin drives CD73-dependent generation of immunosuppressive adenosine Last author DOI 10.1101/2021.11.29.470415↗
  20. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. Co-author DOI 10.1084/jem.20190354↗
  21. CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity. Co-author DOI 10.18632/oncotarget.25088↗
  22. Expression of estrogen receptor beta isoforms in pancreatic adenocarcinoma. Last author DOI 10.18632/oncotarget.26503↗
  23. New insights into plasticity of pancreatic cancer: cancer to acinar cell reprogramming by the basic helix-loop-helix transcription factor E47. Co-author DOI 10.1097/mpa.0000000000000374↗
  24. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Co-author DOI 10.1053/j.gastro.2013.09.050↗
  25. The tumor suppressor rpl36 restrains KRAS(G12V)-induced pancreatic cancer. First author DOI 10.1089/zeb.2014.1024↗
  26. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Co-author DOI 10.1007/s00262-012-1324-3↗

Grants 1

  1. Stop the Start: Novel Insights into PanIN Initiation and Progression AWARD pancan:2011-jennifer-bailey-phd-stop-the-start-novel-insights-into-panin

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nirav C Thosani · 11 shared papers, 2021–2026 · strength 2.08
  2. Lincoln N. Strickland · 8 shared papers, 2022–2026 · strength 1.99
  3. Erika Yanil Faraoni · 8 shared papers, 2021–2026 · strength 1.47
  4. Urvinder Kaur Sardarni · 5 shared papers, 2026 · strength 1.37
  5. Curtis Jackson Wray · 6 shared papers, 2021–2026 · strength 0.99
  6. Florencia M. McAllister · 7 shared papers, 2014–2026 · strength 0.88
  7. MacKenzie V. Demmel · 3 shared papers, 2026 · strength 0.81
  8. Khadija Shahab Turabi · 3 shared papers, 2026 · strength 0.78
  9. Mamoun Younes · 5 shared papers, 2018–2024 · strength 0.64
  10. Kathleen E. DelGiorno · 2 shared papers, 2024–2026 · strength 0.62
  11. Putao Cen · 3 shared papers, 2023–2026 · strength 0.61
  12. Kanchan Singh · 5 shared papers, 2018–2023 · strength 0.56
  13. Jesse L. Cox · 2 shared papers, 2026 · strength 0.53
  14. Rachel R. Tindall · 2 shared papers, 2024 · strength 0.50
  15. Tien C. Ko · 2 shared papers, 2024 · strength 0.50
  16. Anirban Maitra · 5 shared papers, 2014–2021 · strength 0.45
  17. Stephen H Safe · 1 shared paper, 2024 · strength 0.36
  18. Vidhi Chandra · 3 shared papers, 2020–2023 · strength 0.31
  19. Kyle L. McAndrews · 1 shared paper, 2026 · strength 0.29
  20. Majid Momeny · 1 shared paper, 2026 · strength 0.29
  21. Ali Azhdarinia · 1 shared paper, 2026 · strength 0.29
  22. Vahid Khalaj · 1 shared paper, 2026 · strength 0.29
  23. Sruthi Kapliyil Subramanian · 1 shared paper, 2024 · strength 0.28
  24. Vishali Moond · 1 shared paper, 2024 · strength 0.28
  25. Bhaumik S. Brahmbhatt · 1 shared paper, 2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.